Prostate cancer progression, metastasis, and gene expression in transgenic mice

Cancer Research

Volumn 57, Issue 5, 1997, Pages 900-906

  Perez Stable, Carlos ^a,b   Altman, Norman H ^a,b   Mehta, Parmender P ^a,b   Deftos, Leonard J ^c   Roos, Bernard A ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CASTRATION; CONTROLLED STUDY; FETUS; GENE EXPRESSION; HEMIZYGOSITY; HOMOZYGOSITY; MALE; METASTASIS; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTO ONCOGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANDROGENS; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CHROMOGRANIN A; CHROMOGRANINS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, MYC; GENES, P53; GENES, RETINOBLASTOMA; KERATINS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; ORCHIECTOMY; PRECANCEROUS CONDITIONS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TIME FACTORS;

EID: 0031034504     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1996. CA Cancer J. Clin., 46: 5-27, 1996.
2. Carter, H. B., and Coffey, D. S. The prostate: an increasing medical problem. Prostate, 16: 39-48, 1990.
3. Walsh, P. C., and Jewett, H. J. Radical surgery for prostatic cancer. Cancer (Phila.), 45: 1906-1911, 1980.
4. The Leuprolide Study Group, Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med., 311: 1281-1286, 1984.
5. Isaacs, J. T., and Coffey, D. S. Adaptation versus selection as the mechanism responsible for the relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res., 41: 5070-5075, 1981.
6. Rennie, P. S., Bruchovsky, N., and Goldman, A. J. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J. Steroid Biochem. Mol. Biol., 37: 843-847, 1990.
7. Logothetis, C. J., Hoosein, N. M., and Hsieh, J-T. The clinical and biological study of androgen-independent prostate cancer (AI PCa). Semin. Oncol., 21: 620-629, 1994.
8. Mostofi, F. K., Davis, C. J., and Sesterhenn, I. A. Pathology of carcinoma of the prostate, Cancer, 70: 235-253, 1992.
9. Berry, S. J., Coffey, D. S., Walsh, P. C., and Ewing, L. L. The development of human benign prostatic hyperplasia with age. J. Urol., 132: 474-479, 1984.
10. di Sant'Agnese, P. A. Neuroendocrine differentiation in carcinoma of the prostate. Cancer, 70: 254-268, 1992.
11. Aprikian, A. G., Cordon-Cardo, C., Fair, W. R., and Reuter, V. E. Characterization of neuroendocrinc differentiation in human benign prostate and prostatic adenocarcinoma. Cancer (Phila.), 71: 3952-3965, 1993.
12. Hoosein, N. M. Neuropeptides in the progression of prostate cancer. Cancer Bull. (Houst.), 45: 436-441, 1993.
13. Tetu, B., Ro, J. Y., Ayala, A. G., Johnson, D. E., Logothetis, C. J., and Ordonez, N. G. Small cell carcinoma of the prostate: part I. Cancer (Phila.), 59: 1803-1809, 1987.
14. Carney, D. Biology of small cell lung cancer. Lancet, 339: 843-846, 1992.
15. Jelbart, M. E., Russell, P. J., Russell, P., Wass, J., Fullerton, M., Wills, E. J., and Raghavnn, D. Site-specific growth of the prostate xenograft line UCRU-PR-2. Prostate, 14: 163-175, 1989.
16. Bang, Y-J., Pirnia, F., Fang, W-G., Kang, W. K., Sartor, O., Whitesell, L., Ha, M. J., Tsokos, M., Sheahan, M. D., Nguyen, P., Niklinski, W. T., Myers, C. E., and Trepel, J. B. Terminal neurocndocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc. Natl. Acad. Sci. USA, 91: 5330-5334, 1994.
17. Gkonos, P. J., Krongrad, A., and Roos, B. A. Neuroendocrine peptides in the prostate. Urol. Res., 23: 81-87, 1995.
18. Bonkhoff, H., Stein, U., and Remberger, K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum. Pathol., 25: 42-46, 1994.
19. Pollard, M. The Lobound-Wistar rat model of prostate cancer. J. Cell. Biochem., 16H (Suppl.): 84-88, 1992.
20. Bosland, M. C. Animal models for the study of prostate carcinogenesis. J. Cell. Biochem., 16H (Suppl.): 89-98, 1992.
21. Isaacs, J. T. Development and characteristics of the available animal model systems for the study of prostate cancer. In: D. S. Coffey, N. Bruchovsky, W. W. Gardner, M. I. Resnick, and J. P. Karr (eds.), Current Concepts and Approaches to the Study of Prostate Cancer, pp. 513-576. New York: Alan R. Liss, Inc., 1987.
22. Pretlow, T. G., Wolman, S. R., Micale, M. A., Pelley, R. J., Kursh, E. D., Resnick, M. I., Bodner, D. R., Jacobberger, J. W., Delmoro, C. M., Giaconia, J. M., and Pretlow, T. P. Xenografts of primary human prostatic carcinoma. J. Natl. Cancer Inst., 85: 394-398, 1993.
23. Thompson, T. C., Truong, L. D., Timme, T. L., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., and Park, S. H. Transgenic models for the study of prostate cancer. Cancer (Phila.), 71: 1165-1171, 1993.
24. Maroulakou, I. G., Anver, M., Garrett, L., and Green, J. E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA, 91: 11236-11240, 1994.
25. Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., and Rosen, J. M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA, 92: 3439-3443, 1995.
26. Perez-Stable, C., Altman, N. H., Brown, J., Harbison, M., Cray, C., and Roos, B. A. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab. Invest., 74: 363-373, 1996.
27. Perez-Stable, C. Distinct negative regulatory mechanisms involved in the repression of human embryonic ∈- and fetal Gγ-globin genes in transgenic mice. J. Biol. Chem., 269: 33109-33115, 1994.
28. Capetanaki, Y., Kuisk, I., Rothblum, K., and Starnes, S. Mouse vimentin: structural relationship to fos, jun, CREB, and trp. Oncogene, 5: 645-655, 1990.
29. Mehta, P. P., Lokeshwar, B. L., Schiller, P. C., Bendix, M. V., Ostenson, R. C., Howard, G. A., and Roos, B. A. Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mol. Carcinog., 15: 18-32, 1996.
30. Donjacour, A. A., Rosales, A., Higgins, S. J., and Cunha, G. R. Characterization of antibodies to androgen-dependent secretory proteins of the mouse dorsolateral prostate. Endocrinology, 126: 1343-1354, 1990.
31. Auffray, C., and Rougeon, F. Purification of mouse immunoglobulin heavy chain messenger RNAs from total myeloma tumor DNA. Eur. J. Biochem., 107: 303-314, 1980.
32. Wu, H-J., Rozansky, D. J., Parmer, R. J., Gill, B. M., and O'Connor, D. T. Structure and function of the chromogranin A gene. J. Biol. Chem., 266: 13130-13134, 1991.
33. Cunha, G. R., and Donjacour, A. A. Mesenchymal-epithelial interactions: technical considerations. In: D. S. Coffey, N. Bruchovsky, W. A. Gardner, M. I. Resnick, and J. P. Karr (eds.), Current Concepts and Approaches to the Study of Prostate Cancer, pp. 273-282. New York: Alan R. Liss, Inc., 1987.
34. Sugimura, Y., Cunha, G. R., and Donjacour, A. A. Morphogenesis of ductal networks in the mouse prostate. Biol. Reprod., 34: 961-971, 1986.
35. Cunha, G. R., Donjacour, A. A., Cooke, P. S., Mee, S., Bigsby, R. M., Higgins, S. J., and Sugimura, Y. The endocrinology and developmental biology of the prostate. Endocr. Rev., 8: 338-362, 1987.
36. Tutrone, R. F., Ball, R. A., Ornitz, D. M., Leder, P., and Richie, J. P. Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J. Urol., 149: 633-639, 1993.
37. Bostwick, D. G. Prostatic intraepithelial neoplasia (PIN): current concepts. J. Cell. Biochem., 16H (Suppl.): 10-19, 1992.
38. Nagle, R. B., Ahmann, F. R., McDaniel, K. M., Paquin, M. L., Clark, V. A., and Celniker, A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res., 47: 281-286, 1987.
39. Iwamura, M., Wu, G., Abrahamsson, P., Sant'Agnese, P. A., Cockett, A. T. K., and Deftos, L. J. Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology, 43: 667-674, 1994.
40. Iwamura, M., Gershagen, S., Lapets, O., Moynes, R., Abrahamsson, P., Cockett, A., Deftos, L., and Sant'Agnese, P. A. Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia. Hum. Pathol., 26: 797-801, 1995.
41. Marks, J. R., Lin, J., Hinds, P., Miller, D., and Levine, A. J. Cellular gene expression in papillomas of the choroid plexus from transgenic mice that express the simian virus 40 large T antigen. J. Virol., 63: 790-797, 1989.
42. Moritsuka, T., Kobori, O., Morioka, Y., Watanabe, S., Yamaguchi, N., and Sugano, S. Expression level of the retinoblastoma susceptibility gene is elevated in simian virus 40-transformed cells. Oncogene Res., 5: 155-159, 1992.
43. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J-T., Tu, S-M., and Campbell, M. L. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
44. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am. J. Pathol., 143: 390-400, 1993.
45. Lin, J-Y., and Simmons, D. T. The ability of large T antigen to complex with p53 is necessary for the increased life span and partial transformation of human cells by simian virus 40. J. Virol., 65: 6447-6453, 1991.
46. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C-M., and Livingston, D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 58: 1085-1095, 1989.
47. Rinker-Schaeffer, C. W., Partin, A. W., Isaacs, W. B., Coffey, D. S., and Isaacs, J. T. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate, 25: 249-265, 1994.
48. Isaacs, W. B., Bova, G. S., Morton, R. A., Bussemakers, M. J. G., Brooks, J. D., and Ewing, C. M. Molecular biology of prostate cancer. Semin. Oncol., 21: 514-521, 1994.
49. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F., and Allred, D. C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369-3373, 1993.
50. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703-711, 1994.